These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36662739)

  • 1. Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.
    Al Faraidy K; Akbar M; Shehri M; Aljarallah M; Abdin Hussein G; Dashti R; Al Qudaimi A; Al Nouri F; Awan Z; Essam A; Emara A
    PLoS One; 2023; 18(1):e0278821. PubMed ID: 36662739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.
    Gupta M; Wani RJ; Al Faraidy K; Bergeron J; Contreras E; Peña AAG; Mancini GBJ; Padilla F; Lopez AAP; Philip K; Wu J; Mackinnon ES
    Cardiol Ther; 2023 Dec; 12(4):703-722. PubMed ID: 37804438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results.
    Roncancio HM; Lugo-Peña JR; García ÁA; Leal J; Hoyos CA; Beltrán JA; Cruz CL; Paez-Cano C; Pineda-Posada M; Contreras E
    Clin Investig Arterioscler; 2024; 36(1):22-32. PubMed ID: 37438221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study.
    Nanchen D; Carballo D; Bilz S; Rickli H; Koskinas KC; Mach F; Mueller C; Crljenica C; Rossi M; Reichert N; Sudano I
    Adv Ther; 2022 Jan; 39(1):504-517. PubMed ID: 34796465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.
    Sudano I; Krähenbühl S; Mach F; Anstett A; Dhalwani N; Bridges I; Sibartie M; Ray KK
    Ther Adv Cardiovasc Dis; 2024; 18():17539447231213288. PubMed ID: 38183273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
    Ray KK; Bruckert E; Peronne-Filardi P; Ebenbichler C; Vogt A; Bridges I; Sibartie M; Dhalwani N
    Atherosclerosis; 2023 Feb; 366():14-21. PubMed ID: 36696747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
    Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
    Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
    JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study.
    Gupta M; Mancini GBJ; Wani RJ; Ahooja V; Bergeron J; Manjoo P; Pandey AS; Reiner M; Beltran J; Oliveira T; Mackinnon ES
    CJC Open; 2022 Jun; 4(6):558-567. PubMed ID: 35734519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
    Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
    Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
    Lehrke M; Vogt A; Schettler V; Girndt M; Fraass U; Tabbert-Zitzler A; Bridges I; Dhalwani NN; Ray KK
    Adv Ther; 2024 Mar; 41(3):1184-1200. PubMed ID: 38286961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Zhang Y; Zhang Y; Zhang B; Chen Z; Wei Y; Chen P; Chang C; Liu G; Chen K; Ding J; Jiang Z
    Clin Ther; 2022 Jun; 44(6):901-912. PubMed ID: 35581018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
    Rosenson RS; Daviglus ML; Handelsman Y; Pozzilli P; Bays H; Monsalvo ML; Elliott-Davey M; Somaratne R; Reaven P
    Diabetologia; 2019 Jun; 62(6):948-958. PubMed ID: 30953107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
    Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
    Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.